Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Legal Names
Legal name
Similar Companies1000
Inimmune
Inimmune is a biotech company developing immunotherapeutics for various diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
AltruBio
AltruBio is a biopharmaceutical company developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Immunovo
Immunovo is a Dutch biotechnology company focused on developing immunotherapeutic drugs.
Sector
Subsector
Keywords
Location
total rounds
HDT Bio
HDT Bio develops RNA vaccines and therapeutics using LION formulation technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Prima Biomed
announced date
price
Financials
Funding Rounds5
Number of Funding Rounds
Money Raised
Their latest funding was raised on 05.06.2024. Their latest round Post-IPO Equity
Co-Investors
Investors3
Number of lead investors
Number of investors
Platinum AM
Platinum AM is an investment manager that specializes in international shares.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Altium Capital
Altium Capital is a healthcare investment firm that invests in mid-and small-cap equities in the healthcare industry.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Australian Ethical Investment
Australian Ethical Investment Limited is a superannuation and investment fund manager.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders1
Frédéric Triebel
Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist, Dr. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics, leading to 145 publications and 18 patents. Immutep is now part of Prima Biomed Ltd and Dr. Triebel serves as the CSO/CMO of the company.
current job
organization founded
Frédéric Triebel
Employee Profiles3
Deanne Miller
General Counsel and Company Secretary
Activity
Recent News14
The graph reveals the ratio (%) of positive news articles in a chosen time range